Why B2B Life Sciences Brands Are Starting to Think Like Consumer Brands

The boundaries between B2B and B2C marketing are collapsing, and the shift has never been so obvious as for Life Sciences brands right now.

Traditionally, healthcare brands have relied on the authority created by their knowledge, research and credibility. More often than not, that manifests in the form of predictable visual identities and overly complex language that can create distance between brands and the people they're trying to reach.

But now, life science brands are being forced to change and to start thinking more like consumer brands.

Monzo and Revolut led a paradigm shift in terms of what a finance brand has to be. The conventional wisdom was that if it was important (money, insurance, health), it needed to feel ‘grown up’ and, well, boring. The thinking was that anything more informal would lead to a degradation in trust, and people wouldn’t take these brands seriously. Monzo, now worth somewhere in the region of $4.5bn, proved that this wasn’t the case, and other financial services brands have since followed suit. The same thing is now happening for B2B Life Science brands.

Customers, suppliers and partners (and, as a result, investors) now expect B2B life sciences brands to move quickly, make complex ideas accessible and engage audiences in ways that build trust beyond scientific credibility alone.

Three factors driving the shift for B2B Life Science brands

1. Emotional Intelligence matters more

Increasingly, Life Sciences are ‘lifting the lid’ on their science jargon and clinical language. Whereas brands historically used highly technical terms to demonstrate expertise, brands are now expected to be able to communicate their innovations in a way that is more accessible. Broadly speaking, health brands used to communicate with the approach of ‘trust us, we’re the experts’. The world has changed, and now the expectation is more ‘trust us, here’s why…’.

We’re already seeing this shift manifest in emerging health technologies. Neurotech brands are no longer positioning themselves purely around clinical efficacy, but around lifestyle, identity and emotional wellbeing. Wearables designed to optimise sleep, focus and cognitive resilience are increasingly marketed through the lens of self-understanding and everyday performance rather than medical intervention alone. The language of healthcare is becoming more human, experiential and emotionally resonant.

Healthcare may be evidence-led, but decisions are still being made by humans navigating uncertainty, pressure and risk. Life science brands that understand this are better placed to earn trust, shape perceptions and attract investment.

2. Everything needs to move a little faster - especially Life Science brands

Historically, the incentives to move slowly and cautiously prevailed for Life Science brands. It was far better to be 100% belt and braces than get something wrong. This mindset was underpinned by there being almost no downside to moving slowly when it came to marketing and comms.

The world has moved on. Just like consumer brands, the speed of innovation has increased in the B2B Life Sciences space. This has led to the need for brands to move faster when it comes to marketing. B2B is used to perfection, and taking the time to get to that state, consumer brands move faster and iterate, earning trust from customers by talking about ‘always improving with your help’.

Consumers are also becoming accustomed to healthcare support that is continuous, responsive and always available. Emerging AI-enabled care systems are designed to reduce friction, coordinate family health and offer ambient support in real time. These expectations inevitably influence how B2B healthcare brands are expected to communicate too: faster, more adaptive and more human.

Technology, especially AI, plays a role here, but as an enhancer of human interaction, not a replacement for it. Simply put, B2B Life Sciences brands are realising that in a real-time information environment, the relevance of their work has a shelf life and that agility outperforms perfection in this rapidly changing landscape.

3. Communities drive influence more than institutions

There's been a profound shift in where influence lives. A brand must actively earn our trust, and consumers are increasingly dubious about claims made directly from brands, particularly where these lack third-party endorsements. The 2026 Edelman Trust Barometer report says we trust ‘people like me’ more than big institutions or those different from us. The concept of decentralised ownership means people lean towards a human voice, especially when what matters to that person also matters to them.

As consumers we now take advice from our peers over advice from institutions at the top. Authority used to flow almost entirely from institutions such as academic bodies, regulators, major hospitals and expert spokespeople. That hasn’t disappeared, but it’s no longer sufficient on its own. Brands also need to be validated socially. The ‘proof’ is cumulative and conversational.

Brands' roles are shifting from authority to ‘facilitator’ via health forums and communities. Users share their knowledge to help each other, and forward-thinking Life Sciences brands are creating spaces/tools to help communities exchange value, without looking to control the conversation. We’ve seen this influence coming from micro-communities, specialists on forums, on messaging groups and patient advocacy on social platforms. These voices may be smaller individually, but collectively they are strong enough to shape perception.

What this means for life science brands

In short, life science brands need to get comfortable moving quickly, shaping (but not always leading) the conversation and speaking to their audiences in a way that drives emotional resonance.

The shifts outlined above mean we’re seeing brands move away from short-term engagement campaigns in favour of investing in longer-term brand relationships that are built over time and are less about immediate outcomes.

The Life Sciences brands succeeding today aren’t abandoning scientific rigour — they’re translating it differently. They’re learning from consumer brands that trust is no longer built purely through authority, but through accessibility, responsiveness and human relevance. In a world shaped by real-time information, decentralised influence and rising expectations around experience, the strongest healthcare brands won’t simply communicate expertise. They’ll make people feel understood.